Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
暂无分享,去创建一个
[1] J. Bourhis,et al. Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial , 2005, Bone Marrow Transplantation.
[2] S. Mineishi,et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study , 2005, Bone Marrow Transplantation.
[3] P. Staber,et al. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation , 2005, Bone Marrow Transplantation.
[4] I. Bruns,et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma , 2005, Bone Marrow Transplantation.
[5] V. Diehl,et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial , 2004, Bone Marrow Transplantation.
[6] P. Musto,et al. Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies. , 2004 .
[7] C. Soussain,et al. Pegfilgrastim after High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cells Transplantation. A Single-Centre Experience in 15 Patients. , 2004 .
[8] L. Roskos,et al. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. , 2004, Journal of pharmaceutical sciences.
[9] P. Mol,et al. Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures , 2004, Bone Marrow Transplantation.
[10] A. Farese,et al. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques , 2003, Bone Marrow Transplantation.
[11] J. Vose,et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Hackett,et al. Fixed-dose Pegfilgrastim is Safe and Allows Neutrophil Recovery in Patients with Non-Hodgkin's Lymphoma , 2003, Leukemia & lymphoma.
[13] J. Wingard,et al. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation. , 2002, Cytotherapy.
[14] F. Holmes,et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Â. Maiolino,et al. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation , 2002, Bone Marrow Transplantation.
[16] J. Garcia-conde,et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period , 2002, Bone Marrow Transplantation.
[17] L. R. Hill,et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Dini,et al. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial. , 2002, Haematologica.
[19] H. Einsele,et al. Definitions of infectious diseases and complications after stem cell transplant , 2002 .
[20] A. Toor,et al. Infections during mobilizing chemotherapy and following autologous stem cell transplantation , 2001, Bone Marrow Transplantation.
[21] J. Crawford,et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] T. Ulich,et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.
[23] V. Bours,et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. , 1999, Haematologica.
[24] H. Atkins,et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation , 1998, Bone Marrow Transplantation.
[25] J. Radford,et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. , 1998, British Journal of Cancer.
[26] B. Sautois,et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells , 1998, Transfusion.
[27] D. Winfield,et al. G‐CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial , 1997, British journal of haematology.
[28] J. Hainsworth,et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers , 1997, Bone Marrow Transplantation.
[29] Y. Sugiyama,et al. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. , 1996, Drug metabolism reviews.
[30] J. Gabrilove,et al. Filgrastim (r-metHuG-CSF): the first 10 years. , 1996, Blood.
[31] D. Blaise,et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. , 1996, Bone marrow transplantation.
[32] N. Schmitz,et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.
[33] E. Pearlman,et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] W. Velasquez,et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. Chopra,et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. , 1993, Blood.
[36] W. Petros,et al. Pharmacokinetics and Administration of Colony‐Stimulating Factors , 1992, Pharmacotherapy.
[37] C Delgado,et al. The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.
[38] G. Leone,et al. Autologous peripheral blood stem cell transplantation in hematological malignancies. , 1990, Haematologica.
[39] George Morstyn,et al. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor , 1989 .
[40] R. Epstein,et al. Analysis of early infectious complications after autologous bone marrow transplantation , 1988, Cancer.